Navigation Links
Celsion Corporation to Hold Year-End 2012 Financial Results Conference Call On Monday, March 18, 2013
Date:3/12/2013

LAWRENCEVILLE, N.J., March 12, 2013 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN), a leading oncology drug development company, today announced that it will hold a conference call to discuss year-end 2012 results at 11:00 a.m. ET on Monday, March 18, 2013. To participate in the call, interested parties may dial 1-888-312-3048 (Toll-Free/North America) or 1-719-457-1512 (International/Toll) and ask for The Celsion Corporation Year-End 2012 Financial Results Conference Call to register ten minutes before the call is scheduled to begin. The call will also be broadcast live on the internet at http://www.celsion.com.

The call will be archived for replay on Monday, March 18, 2013 at 2:00 p.m. ET and will remain available until Monday, April 1, 2013. The replay can be accessed at 1-877-870-5176 (Toll-Free/North America) or 1-858-384-5517 (International/Toll) using Conference ID: 4075429. An audio replay of the call will also be available on the Company's website, http://www.celsion.com, for 30 days after 2:00 p.m. ET on Monday, March 18, 2013.

About Celsion Corporation

Celsion is a leading oncology company dedicated to the development and commercialization of innovative cancer drugs including tumor-targeting treatments using focused heat energy in combination with heat-activated liposomal drug technology. Celsion has research, license, or commercialization agreements with leading institutions such as the National Institutes of Health, Duke University Medical Center, University of Hong Kong, the University of Pisa, the UCLA Department of Medicine, the Kyungpook National University Hospital, the Beijing Cancer Hospital and the University of Oxford.

For more information on Celsion, visit our website: http://www.celsion.com.

Celsion wishes to inform readers that forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, unforeseen changes in the course of research and development activities and in clinical trials by others; possible acquisitions of other technologies, assets or businesses; possible actions by customers, suppliers, competitors, regulatory authorities; and other risks detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission.

Investor Contact

Jeffrey W. Church
Sr. Vice President – Corporate Strategy &
Investor Relations
609-482-2455
jchurch@celsion.com


'/>"/>
SOURCE Celsion Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Endeavor Power Corporation Introduces Its Proprietary FDA Cleared Target System Platform Technology
2. MGC Diagnostics Corporation Reports 2013 First Fiscal Quarter Operating Results
3. Presage Biosciences Announces Strategic Research Alliance with Celgene Corporation
4. TauRx Pharmaceuticals Receives $10.5m Follow-On Investment from Dundee Corporation
5. MGC Diagnostics Corporation Announces Partnership with Frontera Strategies, LP
6. Volcano Corporation Announces Webcast Of March Seventh Analyst Day
7. TechPrecision Corporation Receives Nuclear Order for $860,000
8. United Therapeutics Corporation Reports 2012 Fourth Quarter and Annual Financial Results
9. Precision Optics Corporation, Inc. Operating Results for Six Months Ended December 31, 2012 and Recent Operating Activities
10. Psychemedics Corporation Announces Record Revenues For 2012; Declares 66th Consecutive Quarterly Dividend
11. MGC Diagnostics Corporation to Report First Quarter Fiscal 2013 Financial Results on Tuesday, March 5, 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... Feb 17, 2017 Research and Markets has announced ... Report" report to their offering. ... The report provides separate comprehensive analytics for the US, ... , Asia-Pacific , and Rest of World. Annual estimates ... six-year historic analysis is provided for these markets. Market data and analytics ...
(Date:2/17/2017)... NEW YORK , Feb. 17, 2017   ... other side effects allegedly associated with use of the ... Philadelphia Court of Common Pleas, ... a mass tort program. According to a notice posted ... scheduled to convene a meeting on March 9, 2017 ...
(Date:2/17/2017)... , Feb. 17, 2017   FormFast , ... announced a new partnership with Engage , one ... United States . FormFast will serve as the ... Engage,s implementations with MEDITECH .  ... essential functionality to complement and enhance the electronic health ...
Breaking Medicine Technology:
(Date:2/18/2017)... ... February 18, 2017 , ... ProParagraph Fashion ... Film Studios ’ ProParagraph Fashion Volume 2 for all multi-line FCPX project needs. ... Users can pick and choose from hand-crafted trend-setting designs with smooth animations that ...
(Date:2/17/2017)... CA (PRWEB) , ... February 17, 2017 , ... ... focus on foundational and sustainable systems change designed to further positively impact the ... “The Board of Trustees has long considered it our duty to seriously consider ...
(Date:2/17/2017)... Palos Verdes, CA (PRWEB) , ... February 17, ... ... and emotional flow is Dr. Carol Francis' goals for each and ... Retreat Conference, Dr. Carol Francis will demonstrate five different brainwave tools which help ...
(Date:2/17/2017)... ... February 17, 2017 , ... Program will serve ... Health and the U.S. Soccer Foundation announced today that they have awarded nine ... for Success, the Foundation’s soccer mentoring program, teaches kids the fundamentals of soccer ...
(Date:2/17/2017)... ... 2017 , ... Cancer diagnostics workflow solution provider Inspirata, Inc., ... 22 in San Francisco. As part of the Tri-Conference expo, which is open ... as well as its new precision medicine platform, “Crosswalk Insight: Oncology™.” , Inspirata ...
Breaking Medicine News(10 mins):